INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) Wednesday said its
SURMOUNT-OSA phase 3 studies of tirzepatide in people with obstructive sleep
apnea (OSA) and obesity reached their primary goals.

OSA is a sleep-related breathing disorder in which breathing stops for brief
periods of time during sleep. OSA can cause serious health problems including
heart disease, stroke, diabetes etc.

SURMOUNT-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA
and obesity who were not on positive airway pressure (PAP) therapy for 52 weeks.
SURMOUNT-OSA Study 2 evaluated tirzepatide in adults with moderate-to-severe
OSA and obesity who were on PAP therapy for 52 weeks.

In both the studies, tirzepatide reduced sleep apnea severity by up to nearly
two-third, compared to placebo, achieving the primary endpoints. The overall
safety profile of tirzepatide in SURMOUNT-OSA studies was similar to previously
reported SURMOUNT and SURPASS trials.

Lilly said it plans to submit these data for FDA and other global regulatory
reviews beginning mid-year.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX